Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Providing Rapid Testing Solutions and Services as Pharmacists’ Roles Expand
- The pharmacy practice is undergoing an evolution that will see pharmacies play a more significant role in patient care
- Expanded pharmacy technology has allowed pharmacists to better document patient care and results, and Avricore is playing a central role in making this possible
- The company’s HealthTab(TM) platform supports multiple rapid, lab-accurate testing instruments, and acts as a network for exchanging and reporting data/results
- Point-of-care testing has numerous benefits, including improved outcomes and quality of life for patients, limiting the spread of infectious diseases, faster treatment, shorter recovery times, and relieving overworked personnel in primary care centers
Health diagnostics technology innovator, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), is committed to moving pharmacy forward. Through its flagship HealthTab(TM) platform, the company turns pharmacies into community diagnostic centers, enabling pharmacists to take on more responsibilities in primary health services. With the community pharmacy practice experiencing an important transformation that will alter how the public thinks of community pharmacists’ role, Avricore is playing a central role in promoting this paradigm shift.
“Many factors are coinciding to set up community pharmacy for an exciting evolution that will continue to grow in the coming years,” reads an article from the October issue of the Pharmacy Times’ Pharmacy Careers publication (https://nnw.fm/0wXO9). “The business model of health care is rapidly changing as communities need their pharmacies to meet gaps in care. Meanwhile, pharmacy technology has expanded to allow pharmacists to better document patient care and outcomes.”
On the pharmacy technology end of the factor-based spectrum is Avricore’s HealthTab platform. HealthTab supports several rapid, lab-accurate testing devices and acts as a network for data exchange and reporting. The integrated devices offer quick onsite results covering infectious diseases, such as COVID-19, influenza A & B, strep, and RSV, as well as chronic conditions, namely diabetes and heart disease (https://nnw.fm/40TGO). HealthTab then shares the data with the patients, doctors, and pharmacists, allowing them to track results to ensure targets are being met.
Avricore’s system offers proper planning, setup, and execution of point-of-care testing (“POCT”) in pharmacies with a bevy of accompanying benefits. For example, rapid results from POCT can help limit the spread of infectious diseases and promote shorter recovery times, improved outcomes, a better quality of life, and faster treatment. Additionally, the availability of POCT services for infectious diseases at pharmacies would help relieve the overworked personnel and nurses at urgent care centers and primary care stations, especially with the ongoing COVID-19 pandemic (https://nnw.fm/1Pv3S).
In understanding the underlying advantages of the POCT infrastructure it has built, Avricore is growing its platform’s reach in Canada. Last month, the company announced it had expanded to Western Canada with the rollout of HealthTab in select Shoppers Drug Mart stores in British Columbia.
“The launch in Shoppers Drug Mart pharmacies in Ontario has been very successful, and we are very happy to see the program lay the groundwork for expansion,” commented AVCR CEO Hector Bremner in an October 26 press release (https://nnw.fm/XDDhQ). “Having a real-time patient observation program reporting seamlessly across 3,000 kilometers is very unique and we are very proud to deliver this innovation.”
Avricore’s HealthTab, which dovetails with the emerging industry trends in the pharmacy practice, is also capitalizing on the rapidly growing global POCT market. Global Market Insights expects the market size to reach $51.8 billion by 2027, representing a CAGR of more than 7.4% during the forecast period, which runs from 2021 (https://nnw.fm/9DhvM).
For more information, visit the company’s website at www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://nnw.fm/AVCRF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The pharmacy practice is undergoing an evolution that will see pharmacies play a more significant role in patient care
- Expanded pharmacy technology has allowed pharmacists to better document patient care and results, and Avricore is playing a central role in making this possible
- The company’s HealthTab(TM) platform supports multiple rapid, lab-accurate testing instruments, and acts as a network for exchanging and reporting data/results
- Point-of-care testing has numerous benefits, including improved outcomes and quality of life for patients, limiting the spread of infectious diseases, faster treatment, shorter recovery times, and relieving overworked personnel in primary care centers
Health diagnostics technology innovator, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), is committed to moving pharmacy forward. Through its flagship HealthTab(TM) platform, the company turns pharmacies into community diagnostic centers, enabling pharmacists to take on more responsibilities in primary health services. With the community pharmacy practice experiencing an important transformation that will alter how the public thinks of community pharmacists’ role, Avricore is playing a central role in promoting this paradigm shift.
“Many factors are coinciding to set up community pharmacy for an exciting evolution that will continue to grow in the coming years,” reads an article from the October issue of the Pharmacy Times’ Pharmacy Careers publication (https://nnw.fm/0wXO9). “The business model of health care is rapidly changing as communities need their pharmacies to meet gaps in care. Meanwhile, pharmacy technology has expanded to allow pharmacists to better document patient care and outcomes.”
On the pharmacy technology end of the factor-based spectrum is Avricore’s HealthTab platform. HealthTab supports several rapid, lab-accurate testing devices and acts as a network for data exchange and reporting. The integrated devices offer quick onsite results covering infectious diseases, such as COVID-19, influenza A & B, strep, and RSV, as well as chronic conditions, namely diabetes and heart disease (https://nnw.fm/40TGO). HealthTab then shares the data with the patients, doctors, and pharmacists, allowing them to track results to ensure targets are being met.
Avricore’s system offers proper planning, setup, and execution of point-of-care testing (“POCT”) in pharmacies with a bevy of accompanying benefits. For example, rapid results from POCT can help limit the spread of infectious diseases and promote shorter recovery times, improved outcomes, a better quality of life, and faster treatment. Additionally, the availability of POCT services for infectious diseases at pharmacies would help relieve the overworked personnel and nurses at urgent care centers and primary care stations, especially with the ongoing COVID-19 pandemic (https://nnw.fm/1Pv3S).
In understanding the underlying advantages of the POCT infrastructure it has built, Avricore is growing its platform’s reach in Canada. Last month, the company announced it had expanded to Western Canada with the rollout of HealthTab in select Shoppers Drug Mart stores in British Columbia.
“The launch in Shoppers Drug Mart pharmacies in Ontario has been very successful, and we are very happy to see the program lay the groundwork for expansion,” commented AVCR CEO Hector Bremner in an October 26 press release (https://nnw.fm/XDDhQ). “Having a real-time patient observation program reporting seamlessly across 3,000 kilometers is very unique and we are very proud to deliver this innovation.”
Avricore’s HealthTab, which dovetails with the emerging industry trends in the pharmacy practice, is also capitalizing on the rapidly growing global POCT market. Global Market Insights expects the market size to reach $51.8 billion by 2027, representing a CAGR of more than 7.4% during the forecast period, which runs from 2021 (https://nnw.fm/9DhvM).
For more information, visit the company’s website at www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://nnw.fm/AVCRF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
